Pancreatic Cancer Research

ResearcherKitasato University HospitalActive in the last 2 years

Yusuke Kumamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9383-4754; OpenAlex author ID A5031008177, A5057517062. Sources: OpenAlex.

Their work

Papers
7 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 2 papers · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 2 papers

Papers 7

  1. Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: A supplementary analysis of JCOG1407. Co-author DOI 10.1016/j.pan.2025.02.005↗
  2. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  3. High likelihood of BRCA2 reversion mutation in pancreatic cancer post-platinum-based chemotherapy: a case study. Co-author DOI 10.1007/s13691-024-00715-0↗
  4. CAFs-Associated Genes (CAFGs) in Pancreatic Ductal Adenocarcinoma (PDAC) and Novel Therapeutic Strategy. First author DOI 10.3390/ijms25116003↗
  5. Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer. Co-author DOI 10.1111/cas.14134↗
  6. Dissected peripancreatic tissue margin is a critical prognostic factor and is associated with a K-ras gene mutation in pancreatic ductal adenocarcinoma. First author DOI 10.3892/ol.2018.9839↗
  7. [Conversion Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer Following Gemcitabine plus Nab-Paclitaxel - A Case Report]. Co-author PMID 28223678↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keishi Yamashita · 3 shared papers, 2019–2024 · strength 0.62
  2. Nobuyuki Nishizawa · 3 shared papers, 2019–2024 · strength 0.37
  3. Kosuke Okuwaki · 3 shared papers, 2017–2024 · strength 0.35
  4. Chika Kusano · 1 shared paper, 2024 · strength 0.21
  5. Masafumi Watanabe · 1 shared paper, 2024 · strength 0.21
  6. Kai Adachi · 1 shared paper, 2024 · strength 0.21
  7. Taro Hanaoka · 1 shared paper, 2024 · strength 0.21
  8. Taro Shibuki · 1 shared paper, 2025 · strength 0.19
  9. Yusuke Sano · 1 shared paper, 2025 · strength 0.19
  10. Satoshi Kobayashi · 1 shared paper, 2025 · strength 0.19
  11. Masafumi Ikeda · 1 shared paper, 2025 · strength 0.19
  12. Yukiko Takayama · 1 shared paper, 2025 · strength 0.19
  13. Masato Ozaka · 1 shared paper, 2025 · strength 0.19
  14. Masashi Kanai · 1 shared paper, 2025 · strength 0.19
  15. Akiko Todaka · 1 shared paper, 2025 · strength 0.19
  16. Akihiro Ohba · 1 shared paper, 2025 · strength 0.19
  17. Junji Furuse · 1 shared paper, 2025 · strength 0.19
  18. Nao Fujimori · 1 shared paper, 2025 · strength 0.19
  19. Makoto Ueno · 1 shared paper, 2025 · strength 0.19
  20. Akio Katanuma · 1 shared paper, 2025 · strength 0.19
  21. Masahiko Watanabe · 2 shared papers, 2017–2019 · strength 0.14
  22. Shuji Nakamoto · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.